The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

TAKE PARTIAL PROFITS ON FLEXION THERAPEUTICS $FLXN

July 13, 2017

This post was just published on ZYX Buy Change Alert.  FLXN is long from 18.75.  The stock is trading at $23.19 as of this writing.  The original thesis remains intact. The new target zone is $38 to $44.  However, there are many very near term risks that could cause the stock to pull back.  Please remember this is a biotech stock and biotech stocks can be very volatile. Consider taking partial profits on a 10% tranche right here and consider continuing to hold the remaining 10% as part of your speculative portfolio. A special note to new subscribers: Please see Trade Management

Read More »

A NEW FEAR OF TRUMP IMPEACHMENT COULD MOVE STOCKS, BONDS AND GOLD $GLD $NVDA $AMZN $TSLA $AAPL $QQQ $SPY $IWM $TLT $SLV $GOOG $FB $NFLX

July 11, 2017

Successful investors make money by preparing for scenarios without letting their politics cloud their judgement. That’s a difficult task, especially in these partisan times. But I am politically agnostic, and I see my job as helping other investors. The chart To understand the new development today, let us look at an annotated chart. The chart is of the Nasdaq 100 ETF QQQ.  Similar action can be seen in the charts of the S&P 500 ETF SPY, small-cap ETF IWM,  bond ETF TLT, gold ETF GLD, and silver ETF SLV. The reason I picked QQQ is because it has heavy weighting

Read More »

INTELLIGENCE: AMICUS THERAPUTICS JUMPS 23%, SEVEN POTENTIAL BIOTECH BUYOUT TARGETS $FOLD $BMRN $EXEL $INCY $MDVN $RARE $SGEN $TSRO

July 11, 2017

This post was just published on ZYX Buy Change Alert. FOLD plans to submit a new drug application to FDA for the oral precision medicine migalastat for Fabry disease.  The stock is jumping on the news. We are not recommending buying FOLD here but it can be part of a basket on a pullback as discussed below. Based on questions you are asking us, we are republishing the prior post here: INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIA BUYOUT For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to

Read More »

NEW BUY ZONE ON ARENA FOR THOSE NOT IN IT AND NEW TARGETS $ARNA

July 11, 2017

This post was just published on ZYX Buy Change Alert.  New buy zone for those not in ARNA is $20.33 to $22.78.  Maximum position is 20% of the full core position size. New target zone without a buyout is $32 to $34.  In the event of a buyout, a price in the zone of $44 to $52 is possible. Please understand that there is high risk in buying the stock right here without waiting for a pullback. A special note for new subscribers: Please carefully study Trade Management Guidelines for speculative positions, these are the techniques that billionaires and hedge funds use

Read More »

NICE GAINS ON ARENA AS IT JUMPS 25% ON POSITIVE DRUG RESULTS, GAINS NOT AS BIG AS SOME ARE MISTAKENLY THINKING $ARNA

July 11, 2017

This post was published on ZYX Buy Change Alert.   ARNA is long from $16.20.  It is trading at $25 as of this writing.  The company announced positive Phase 2 results for Ralinepag for the treatment of pulmonary arterial hypertension. The gains are not as some are mistakenly thinking.  The stock was originally bought at $1.62. Since then there has been a 10 for 1 reverse split.  So your cost basis is $16.20 not $1.62. What To Do Now Those in the position may consider taking profits on one-third of the position right here around $25.  Move stops on another one-third in

Read More »

UPDATE ON GENERAL ELECTRIC $GE $AMZN

July 10, 2017

This post was just published on ZYX Buy Change Alert.  The following were the three reasons for buying GE: A reputable activist investor has a major stake in GE. This investor has a track record of forcing major corporations into making changes.  Typically the stocks he invests in run up after the changes are made. Perhaps under pressure from this investor, GE appointed a new CEO. The market has run up a lot.  One of the proven strategies to generate outsized risk adjusted returns in bull markets is to find laggards that have not moved up but have a catalyst to move

Read More »

TAKE PARTIAL PROFITS ON CRUDE OIL ETF USO AND MOVE THE STOP ON THE REST $USO $CL_F $UWT $DWT $SCO

July 10, 2017

This post was just published on ZYX Short Sell Change Alert.  Oil ETF USO is short from $9.54 for a short-term trade.  It has now fallen to $8.98 as of the writing in the pre-market and very volatile.  Consider taking profits on 25% of the full core position size right here.  Consider lowering the stop on the remaining 10% in the zone of $9.23 to $9.27. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial.

Read More »

TAKE MORE PARTIAL PROFITS ON INVERSE GOLD MINER ETF DUST AND RAISE STOPS ON THE REST $DUST $GLD $NUGT $SLV

July 7, 2017

This post was just published on ZYX Buy Change Alert.  Inverse gold miner ETF DUST was recently purchased for a short-term trade at an average price of $28.85.  It is trading at $35.38 as of this writing.  Depending upon your total position size, consider taking profits on one-half of the remaining position right here.  Target for the other half remains $37 to $39.43.  Raise the stops on the remaining to $32.73 to $33.23. If you have small account, consider taking profits on the entire position and exit the position. You are receiving less than 2% of the content from our paid services

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content